Acute Myeloid Leukemia in Adolescents and Young Adults (AYAs): A Comparison of Outcomes Between Patients Treated on Childhood or Adult Protocols

Reviewer: Mary Kara Bucci, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 10 de diciembre del 2001

Share article


English

Presenter: William G. Woods
Presenter's Affiliation: Emory University, Atlants, GA and Children's Cancer Group, Arcadia, CA
Type of Session: Scientific

Background
Children with AML are frequently treated with more aggressive regimens than adults, and adults under age 40 are often treated with more aggressive regimens than older adults due to increased treatment-related mortality (TRM). Adolescents and young adults (AYAs) can have the acute, proliferative form of AML often seen in children, yet are often treated on adult protocols. It is unknown whether this produces a difference in outcome in this population. This study compares previously untreated AYAs age 16-21 treated on the superior arm of a pediatric protocol with those treated on adult protocols from a single instituion.

Materials and Methods

  • Patients (pts) age 16-21 from the intensive timing arm of Children's Cancer Group (CCG) 2891 (n=59) were compared with patients of the same age treated at the MD Anderson Cancer Center (MDACC) on adult protocols between 1980 and 2000 (n=54).
  • Regimens used at MDACC include AraC/daunorubicin (1980-85), high dose AraC with or without an antracycline (1986-93), high dose AraC + Fludarabine +/- an anthracyclin (1994-96), AraC + Topotecan +/- cyclophosphamide (1996-2000).
  • Patient groups were similar with regard to all known prognostic factors except for minor differences in age (median 18.9 for MDACC pts vs. 17.2 for CCG pts) and median bone marrow blast percentage (66% for MDACC pts vs. 76% for CCG pts).

    Results

  • At 5 years from diagnosis, event-free survival was 17% for MDACC pts and 47% for CCG pts, p=.007.
  • At 5 years from remission, disease-free survival was 22% for MDACC pts and 60% for CCG pts, p=.003.
  • At 5 years from diagnosis, overall survival was 32% for MDACC pts and 51% for CCG pts, p=.16.
  • At 5 years from remission, overall survival was 41% for MDACC pts and 64% for CCG pts, p=.08.
  • The CCG 2891 trial found no difference in survival between pts under age 16 and pts 16-21.
  • MDACC pts 16-21 had similar survival to MDACC pts 21-41, and to the standard timing arm from CCG.

    Author's Conclusions
    The authors conclude that patients 16 - 21 years old treated according to the intensive timing arm of CCG 2891 fared better than those treated on the adult regimens of MDACC. Patients from this age group fared as well on adult regimens as those treated on inferior (standard timing) arm of CCG 2891.

    Clinical/Scientific Implications
    This retrospective study suggests that adolescents and young adults aged 16-21 have an improved outcome on more intensive regimens. Adult cancer centers may enroll patients of this age group of intergroup pediatric trials. In the future, more intensive therapy may be directed towards adults under age 45, as well.

    Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Amgen.

    English
    News
    Pediatric Regimen Beats Adult Chemo for Young Adults With ALL

    Apr 24, 2012 - Adolescent and young adult patients with acute lymphoblastic leukemia who are treated with pediatric-inspired regimens exhibit lower all-cause mortality, higher complete remission and event-free survival rates, and lower relapse rates compared with those treated with conventional adult-chemotherapy regimens, according to a study published in the May issue of the American Journal of Hematology.



  • I Wish You Knew

    How cancer patients have changed my life

    View More



    Blogs and Web Chats

    OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




    OncoLink OncoPilot

    Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

    Más información